{"filing":{"accession_number":"0001935979-26-000072","cik":"0001935979","ticker":"BHVN","company_name":"Biohaven Ltd.","form":"8-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"bhvn-20260826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/bhvn-20260826.htm"},"events":[{"id":29602,"run_id":27117,"accession_number":"0001935979-26-000072","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Biohaven's subsidiary BBIL entered into an exclusive worldwide license agreement with SK Biopharmaceuticals on August 26, 2026, granting SK rights to the Kv7 ion channel platform and lead candidate opakalim. The transaction includes $400 million in upfront cash ($350 million at closing, $50 million in 2027), up to $150 million in development and regulatory milestones, tiered royalties on net sales, and SK's assumption of $245 million in contingent obligations, representing a significant strategic disposition of intellectual property.","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-08-26","form":"8-K","submitted_at":null,"items":[{"id":31936,"accession_number":"0001935979-26-000072","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Biohaven's subsidiary BBIL entered into a material definitive License Agreement with SK Biopharmaceuticals on August 26, 2026, granting an exclusive worldwide license to the Kv7 ion channel platform led by opakalim. The transaction involves $400 million in upfront cash ($350M at closing, $50M in one year), up to $150 million in development/regulatory milestones, tiered royalties on net sales, and assumption of $245 million in contingent obligations. This constitutes a material acquisition/disposition of intellectual property rights and represents a significant strategic transaction that would materially affect a reasonable investor's assessment of Biohaven's financial position and pipeline monetization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:40:41.413822+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31937,"accession_number":"0001935979-26-000072","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Biohaven entered into a strategic global licensing agreement with SK Biopharmaceuticals under which SK obtains an exclusive worldwide license to Biohaven's Kv7 ion channel platform and lead candidate opakalim. The transaction involves $400 million in near-term cash consideration ($350 million at closing, $50 million in 2027), up to $150 million in development and regulatory milestones, tiered royalties on global net sales, and SK's assumption of $245 million in Knopp Biosciences obligations. This constitutes a material disposition of intellectual property and a significant capital transaction that would materially affect a reasonable investor's assessment of Biohaven's financial position, pipeline strategy, and long-term value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:40:41.413822+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31936,"accession_number":"0001935979-26-000072","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Biohaven's subsidiary BBIL entered into a material definitive License Agreement with SK Biopharmaceuticals on August 26, 2026, granting an exclusive worldwide license to the Kv7 ion channel platform led by opakalim. The transaction involves $400 million in upfront cash ($350M at closing, $50M in one year), up to $150 million in development/regulatory milestones, tiered royalties on net sales, and assumption of $245 million in contingent obligations. This constitutes a material acquisition/disposition of intellectual property rights and represents a significant strategic transaction that would materially affect a reasonable investor's assessment of Biohaven's financial position and pipeline monetization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:40:41.413822+00:00","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-08-26"},{"id":31937,"accession_number":"0001935979-26-000072","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Biohaven entered into a strategic global licensing agreement with SK Biopharmaceuticals under which SK obtains an exclusive worldwide license to Biohaven's Kv7 ion channel platform and lead candidate opakalim. The transaction involves $400 million in near-term cash consideration ($350 million at closing, $50 million in 2027), up to $150 million in development and regulatory milestones, tiered royalties on global net sales, and SK's assumption of $245 million in Knopp Biosciences obligations. This constitutes a material disposition of intellectual property and a significant capital transaction that would materially affect a reasonable investor's assessment of Biohaven's financial position, pipeline strategy, and long-term value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:40:41.413822+00:00","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-08-26"}]}